Disc Medicine is a healthcare company focused on developing innovative therapies for patients with blood disorders. Its core products include treatments targeting iron overload and related conditions. The company primarily operates in the biopharmaceutical segment, with revenue sources stemming from research and development collaborations and potential future product sales.
The investment profile of Disc Medicine is more aligned with growth investors due to its focus on developing new therapies and the potential for significant future returns. However, the high risk associated with its current financial performance may deter conservative investors. The stock may appeal to those with a longer investment horizon who are willing to accept volatility for potential growth.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-05-08 15:28 | — | Sell | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-05-08 05:26 | Sell | Sell | Компания Disc Medicine демонстрирует отрицательную динамику акций на длительном горизонте, а также отрицательный EPS, что указывает на высокие финансовые риски. |
| 2026-04-29 02:46 | Hold | Sell | Компания Disc Medicine демонстрирует высокие колебания цен и отрицательный EPS, что указывает на высокие риски. Однако недавний рост за 20 дней может свидетельствовать о потенциальном восстановлении. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-05-14 12:09 | Morgan Stanley | Target Raised | 75 → 80 | 69.3 |
| 2026-02-17 13:34 | Wedbush | Target Lowered | 110 → 88 | 60.28 |
| 2026-02-17 13:21 | Cantor Fitzgerald | Target Lowered | 153 → 125 | 60.24 |
